

Technical Information

Intact Fibroblast Growth Factor 23 iFGF23

Cat. No.:	BI-20700
Tests:	96
Method:	ELISA
Range:	0 – 1600 pg/ml
LLOQ:	12.5 pg/ml (STD2 50 pg/ml)
Incubation time:	3 h / 30 min
Sample volume:	50 µl
Sample type:	EDTA/Heparin/Citrate plasma, serum
Sample preparation:	Centrifuge freshly collected blood as soon as possible Store centrifuged samples at -20°C for longer storage. Samples are stable up to 4 freeze and thaw cycles. Hemolyzed or lipemic samples may cause erroneous results.
Reference values:	Median EDTA plasma (n=22): 24.4 pg/ml Median Heparin plasma (n=22): 26.14 pg/ml Median Citrate plasma (n=22): 17.4 pg/ml Median serum (n=22): 14.8 pg/ml
Species:	Human

Intended use:

FGF23 (fibroblast growth factor 23) is a member of the fibroblast growth factor family and controls phosphate and vitamin D homeostasis. The full-length protein comprises 251 amino acids including a 24 amino acid signal peptide. The N-terminal FGF region of FGF23 is separated from the C-terminal region by a proteolytic cleavage site. A fraction of FGF23 is proteolytically processed between arginine179 and serine180 to generate N-terminal and C-terminal fragments. Therefore, the main forms of FGF23 present in human circulation are hormonally intact FGF23 and inactive N-terminal and C-terminal fragments. FGF23 binds to FGF receptor 1c (FGFR1c) with its N-terminal region, while the C-terminal region interacts with the co-receptor α -Klotho to confer high-affinity binding to the receptor. FGFR1c and α -Klotho are expressed in the distal nephron and the parathyroid gland. Co-receptor independent signaling of FGF23 has been described for other FGFRs, which are expressed in a variety of tissues. The main source of FGF23 are osteocytes in the bone.

Intended applications:

- Bone diseases
- Cancer
- Cardiovascular diseases
- Endocrine disorders
- Metabolic disorders
- Kidney diseases

For further information please contact / Für weitere Informationen wenden Sie sich bitte an /
Pour plus d'informations, veuillez contacter:

www.tecomedical.com



A EUROBIO SCIENTIFIC COMPANY

Switzerland / Headquarters
TECO medical AG
Gewerbstrasse 10
4450 Sissach
Phone +41 61 985 81 00
Fax +41 61 985 81 09
Mail info@tecomedical.com

Germany
TECO medical GmbH
Wasserbreite 57
32257 Bünde
Phone +49 52 23 985 99 99
Fax +49 52 23 985 99 98
Mail info@tecomedical.com

Benelux
TECO medical Benelux BV
Prins Willem-Alexanderlaan 301
7311 SW Apeldoorn, The Netherlands
Phone +31 30 307 87 30
Fax +31 30 307 49 39
Mail benelux@tecomedical.com

Austria
TECO medical AG
Phone 0800 20 40 66
Fax 0800 20 40 55
Mail info@tecomedical.com